EA201700123A1 - Способ прогнозирования варианта лекарственного препарата для лечения депрессии - Google Patents

Способ прогнозирования варианта лекарственного препарата для лечения депрессии

Info

Publication number
EA201700123A1
EA201700123A1 EA201700123A EA201700123A EA201700123A1 EA 201700123 A1 EA201700123 A1 EA 201700123A1 EA 201700123 A EA201700123 A EA 201700123A EA 201700123 A EA201700123 A EA 201700123A EA 201700123 A1 EA201700123 A1 EA 201700123A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
pea
patient
treatment
predicting
Prior art date
Application number
EA201700123A
Other languages
English (en)
Other versions
EA034419B1 (ru
Inventor
Нориюки Кавамура
Хаджиме Сато
Куми Ямаки
Тамаки Фуджимори
Хироюки Ямамото
Ёшиаки Онаши
Original Assignee
Хьюман Метаболоми Текнолоджис Инк.
Гёкикай Медикал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хьюман Метаболоми Текнолоджис Инк., Гёкикай Медикал Корпорейшн filed Critical Хьюман Метаболоми Текнолоджис Инк.
Publication of EA201700123A1 publication Critical patent/EA201700123A1/ru
Publication of EA034419B1 publication Critical patent/EA034419B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Задача: обеспечить способ, в котором фосфоэтаноламин (ФЭА), выступающий в качестве биомаркёра депрессии, непосредственно связан с лечением. Решение: способ прогнозирования вариантов лекарственных препаратов для лечения депрессии включает следующие шаги: (1) измерение уровня ФЭА в крови, взятой у пациента с подозрением на депрессию; (2) определение того, является ли уровень ФЭА в крови пациента ниже, чем эталонное значение, отличающееся тем, что если измеренное значение пациента ниже значений, полученных у здоровых людей, пациент страдает депрессией, характеризуемой пониженным уровнем ФЭА, выступающим в качестве индикатора; и (3) прогнозирование вариантов лекарственных препаратов для лечения депрессии на основании наличия или отсутствия пониженного уровня ФЭА в крови пациента.
EA201700123A 2014-09-26 2015-09-24 Способ выбора лекарственного препарата для лечения депрессии EA034419B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014196043 2014-09-26
PCT/JP2015/076903 WO2016047677A1 (ja) 2014-09-26 2015-09-24 うつ病治療薬の選択肢を予測する方法

Publications (2)

Publication Number Publication Date
EA201700123A1 true EA201700123A1 (ru) 2017-09-29
EA034419B1 EA034419B1 (ru) 2020-02-06

Family

ID=55581200

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700123A EA034419B1 (ru) 2014-09-26 2015-09-24 Способ выбора лекарственного препарата для лечения депрессии

Country Status (7)

Country Link
US (1) US20170176412A1 (ru)
EP (1) EP3190413B1 (ru)
JP (1) JP6709887B2 (ru)
KR (1) KR102118780B1 (ru)
CN (1) CN106716129B (ru)
EA (1) EA034419B1 (ru)
WO (1) WO2016047677A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018061194A1 (ja) * 2016-09-30 2018-04-05 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
WO2018062204A1 (ja) * 2016-09-30 2018-04-05 ヒューマン・メタボローム・テクノロジーズ株式会社 エタノールアミンリン酸の測定方法
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
KR20200049606A (ko) 2018-10-29 2020-05-08 고려대학교 산학협력단 항우울제 추천 방법 및 시스템
KR102120113B1 (ko) 2019-10-31 2020-06-17 모성희 티엠에스(tms)를 이용한 우울증치료 장치
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression
CN113117101A (zh) * 2021-05-28 2021-07-16 南昌大学 一种对抑郁症治疗药物的选项进行预测的方法
CN116500280B (zh) * 2023-06-26 2023-09-12 中国医学科学院北京协和医院 一组诊断颈动脉体瘤的标志物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054347A1 (es) * 2005-04-22 2007-06-20 Wyeth Corp Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
JP2009007278A (ja) * 2007-06-27 2009-01-15 Argenes Inc 線維筋痛症の治療薬
EP2373999A4 (en) * 2008-12-09 2012-11-07 Stephanie Fryar-Williams NEW BIOMARKERS
CN104777314B (zh) * 2009-08-12 2017-01-04 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
US9631224B2 (en) * 2011-11-10 2017-04-25 Human Metabolome Technologies, Inc. Method for measuring ethanolamine phosphate
JP6291158B2 (ja) * 2012-11-21 2018-03-14 サントリーホールディングス株式会社 抗認知症および学習記憶改善剤

Also Published As

Publication number Publication date
KR20170062478A (ko) 2017-06-07
JPWO2016047677A1 (ja) 2017-07-06
KR102118780B1 (ko) 2020-06-03
EP3190413A1 (en) 2017-07-12
EA034419B1 (ru) 2020-02-06
WO2016047677A1 (ja) 2016-03-31
JP6709887B2 (ja) 2020-06-17
CN106716129A (zh) 2017-05-24
CN106716129B (zh) 2019-04-19
US20170176412A1 (en) 2017-06-22
EP3190413A4 (en) 2018-03-28
EP3190413B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
BR112016028958A2 (pt) método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
PH12017501841A1 (en) Method for discriminating symptom of hepatic disease
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112018003528A2 (pt) dispositivo para medição não invasiva de níveis de açúcar no sangue
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
EA201690537A1 (ru) Способы и средства для введения контрастной среды
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
EA201800413A1 (ru) Способ автоматического измерения вязкости крови
TW201612520A (en) Tumor examination composition and test paper for tumor examination
RU2011116505A (ru) Способ диагностики различных форм острого пиелонефрита
MX2017014218A (es) Metodo de diagnostico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albumina en el liquido cefalorraquideo.
UA91642U (ru) Способ определения степени токсемии у пациентов при микросатурнизме
RU2012144141A (ru) Способ оценки вероятности возникновенения переломов при остеопорозе у женщин
RU2014110649A (ru) Способ диагностики развития стенозирования стентов
MX357018B (es) Método de diagnóstico temprano de carcinoma hepatocelular.
EA201690217A1 (ru) Способ и диагностический набор для контроля рассеянного склероза (pc)
Musialowska et al. ENDOCAN CONCENTRATION IN HYPERTENSIVE PATIENTS
RU2012129472A (ru) Способ определения прогрессии рака органов брюшной полости
RU2014154450A (ru) Способ диагностики псориаза
LV15306A (lv) Asins sastrēguma plaušās attīstības riska noteikšanas paņēmiens pneimonijas gadījumā
UA99717U (uk) Спосіб прогнозування досягнення цільового артеріального тиску у хворих з артеріальною гіпертензією та цукровим діабетом

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM